Loading...
XNAS
BNBX
Market cap3mUSD
Dec 05, Last price  
3.00USD
1D
-3.23%
1Q
25.52%
Jan 2017
62.16%
IPO
11.09%
Name

Applied DNA Sciences Inc

Chart & Performance

D1W1MN
XNAS:BNBX chart
P/E
P/S
1.13
EPS
Div Yield, %
Shrs. gr., 5y
143.75%
Rev. gr., 5y
-8.63%
Revenues
3m
-74.33%
018,900121,920873,010295,162519,844968,8481,854,6942,036,2222,721,2249,008,4994,186,4274,751,2603,903,3435,389,0891,931,4979,027,73818,168,67713,367,4433,431,420
Net income
-7m
L-29.70%
-52,610,380-2,410,237-13,304,833-6,802,8983,944,578-7,909,600-10,515,124-7,150,712-17,686,472-13,066,661-11,881,137-12,175,979-12,855,767-11,692,928-8,632,446-12,764,974-16,029,225-8,377,996-9,947,059-6,992,521
CFO
-14m
L+120.52%
-9,116,045-2,883,815-2,251,580-2,926,280-2,468,598-2,455,189-3,761,716-3,960,679-7,870,353-8,512,738-6,965,846-9,896,727-7,479,184-6,917,209-6,861,772-11,143,059-13,387,955-8,976,706-6,217,677-13,711,397

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
IPO date
Aug 24, 2001
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT